Table 1.
Participant characteristic | Non-whitea, n (%) (n = 19) | White, n (%) (n = 61) | Fisher’s p value | ||
---|---|---|---|---|---|
Age | .80 | ||||
13–17 | 9 | (47) | 32 | (52) | |
18–25 | 10 | (53) | 29 | (48) | |
Gender | .24 | ||||
Male | 18 | (95) | 61 | (100) | |
Female | 1 | (5) | 0 | (0) | |
Ethnicity | 1.0 | ||||
Hispanic | 2 | (14) | 8 | (12) | |
Non-Hispanic | 17 | (86) | 53 | (88) | |
Health Insuranceb | <.001 | ||||
Medicaid or VA onlyc | 12 | (63) | 12 | (20) | |
Commercial only | 3 | (16) | 32 | (52) | |
Both | 0 | (0) | 7 | (11) | |
Insured—type unknown | 1 | (5) | 8 | (13) | |
Uninsured | 3 | (16) | 0 | (0) | |
Mother’s education | .78 | ||||
Less than bachelor’s | 14 | (74) | 42 | (69) | |
Bachelor’s or higher | 5 | (26) | 19 | (31) | |
Father’s education | .16 | ||||
Less than bachelor’s | 16 | (84) | 39 | (64) | |
Bachelor’s or higher | 3 | (16) | 22 | (36) | |
Bleeding disorder | .19 | ||||
Hemophilia A | 19 | (100) | 54 | (89) | |
Hemophilia B | 0 | (0) | 7 | (11) | |
Severity | 1.0 | ||||
Moderate | 1 | (5) | 6 | (10) | |
Severe | 18 | (95) | 55 | (90) | |
Inhibitor development | <.01 | ||||
Never | 5 | (26) | 38 | (62) | |
Ever | 14 | (74) | 23 | (38) | |
Treatment regimen | .72 | ||||
On-demand | 3 | (16) | 8 | (13) | |
Prophylaxis | 16 | (84) | 53 | (87) |
aMost (73 %) non-white respondents were black or African-American, 14 % were mixed race, 9 % were Asian, and 5 % were American Indian or Alaskan Native
b n = 78, two patients answered “Don’t Know” to whether or not they had health insurance and were not included
cOnly two patients had VA only insurance; the others had Medicaid only